Success Metrics

Clinical Success Rate
83.0%

Based on 39 completed trials

Completion Rate
83%(39/47)
Active Trials
6(11%)
Results Posted
74%(29 trials)
Terminated
8(15%)

Phase Distribution

Ph phase_3
14
26%
Ph phase_1
31
57%
Ph phase_4
1
2%
Ph phase_2
8
15%

Phase Distribution

31

Early Stage

8

Mid Stage

15

Late Stage

Phase Distribution54 total trials
Phase 1Safety & dosage
31(57.4%)
Phase 2Efficacy & side effects
8(14.8%)
Phase 3Large-scale testing
14(25.9%)
Phase 4Post-market surveillance
1(1.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.3%

39 of 48 finished

Non-Completion Rate

18.8%

9 ended early

Currently Active

6

trials recruiting

Total Trials

54

all time

Status Distribution
Active(6)
Completed(39)
Terminated(9)

Detailed Status

Completed39
Terminated8
Active, not recruiting3
Recruiting3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
54
Active
6
Success Rate
83.0%
Most Advanced
Phase 4

Trials by Phase

Phase 131 (57.4%)
Phase 28 (14.8%)
Phase 314 (25.9%)
Phase 41 (1.9%)

Trials by Status

active_not_recruiting36%
terminated815%
completed3972%
withdrawn12%
recruiting36%

Recent Activity

Clinical Trials (54)

Showing 20 of 54 trialsScroll for more
NCT05039840Phase 2

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Active Not Recruiting
NCT05126277Phase 3

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
NCT06945406Phase 1

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Recruiting
NCT06908707Phase 1

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

Completed
NCT07116889Phase 1

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

Active Not Recruiting
NCT03524092Phase 3

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Completed
NCT04879628Phase 2

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Active Not Recruiting
NCT06408857Phase 1

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Recruiting
NCT06048120Phase 1

A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

Completed
NCT02407236Phase 3

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Completed
NCT03981744Phase 3

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Terminated
NCT03782376Phase 3

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

Completed
NCT01369355Phase 3

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Completed
NCT04178733Phase 1

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

Completed
NCT01009242Phase 1

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Completed
NCT04631562Phase 1

Study of ALXN1820 in Healthy Adult Participants

Completed
NCT01242488Phase 2

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Completed
NCT02568423Phase 1

A Study of Mirikizumab (LY3074828) in Healthy Participants

Completed
NCT04137380Phase 1

A Study of Mirikizumab in Healthy Chinese Participants

Completed
NCT05354349Phase 1

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Completed

Drug Details

Intervention Type
DRUG
Total Trials
54